RCUS / Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates

Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to more_horizontal

Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares more_horizontal

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 6.06% and 45.10%, respectively, for the quarter ended December 2022. Do the more_horizontal

Arcus Biosciences (RCUS), Suzano (SUZ), and Arch Resources (ARCH) has been selected as the top picks with a high net income ratio. more_horizontal

The heavy selling pressure might have exhausted for Arcus Biosciences, Inc. (RCUS) as it is technically in oversold territory now. In addition to this more_horizontal

Arcus Biosciences Inc and Gilead Sciences Inc shares have both taken a tumble after the companies reported positive but not groundbreaking results fro more_horizontal

Shares of Arcus Biosciences Inc. RCUS, -1.23% were down 17.2% in premarket trading on Tuesday, the day after the company said the experimental treatme more_horizontal

Gilead and Arcus notched another win for their cancer program on Monday, pushing GILD stock briefly to a four-year high as RCUS stock gapped higher. T more_horizontal